Securities Code: 300289
Stock Abbreviation: Liderman
Announcement No.: 2026-036
Beijing Liderman Bio-Chemical Co., Ltd.
Announcement on the Adjustment of the Transaction Plan Not Constituting a Major Adjustment to the Restructuring Plan
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Beijing Liderman Bio-Chemical Co., Ltd. (hereinafter referred to as the "Company" or "Listed Company") intends to acquire 235,040,700 shares of Beijing Sanyuan Xiangrui Biotechnology Co., Ltd. (hereinafter referred to as "Sanyuan Xiangrui") (accounting for 61.50% of the issued shares of Sanyuan Xiangrui) (hereinafter referred to as the "Transaction") held by Hainan Baimai Investment Co., Ltd., Hainan Sanyuan Baijia Hui Technology Development Co., Ltd., and Nanjing Baijiarui Enterprise Management Consulting Partnership (Limited Partnership) by paying cash.
On June 12, 2026, the Company held the twelfth meeting of the Sixth Board of Directors, which reviewed and approved the "Proposal on the Adjustment of the Transaction Plan Not Constituting a Major Adjustment to the Restructuring Plan."
I. Specific Content of the Restructuring Plan Adjustment
The main specific content of the restructuring plan adjustment is as follows: